s8790 keap1 targetmol cat Search Results


ml 385  (Selleck Chemicals)
96
Selleck Chemicals ml 385
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Ml 385, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-118-120?v=Selleck+Chemicals
Average 96 stars, based on 1 article reviews
ml 385 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti keap1 f 10  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti keap1 f 10
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Anti Keap1 F 10, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-59-62?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti keap1 f 10 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti 8 ohdg  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti 8 ohdg
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Anti 8 Ohdg, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-86-88?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti 8 ohdg - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti heme oxygenase 1 a 3  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti heme oxygenase 1 a 3
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Anti Heme Oxygenase 1 A 3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-38-43?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti heme oxygenase 1 a 3 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti lamin a c  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti lamin a c
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Anti Lamin A C, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-96-99?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
anti lamin a c - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti gapdh  (Santa Cruz Biotechnology)
97
Santa Cruz Biotechnology anti gapdh
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Anti Gapdh, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pmc12903676-68-102-104?v=Santa+Cruz+Biotechnology
Average 97 stars, based on 1 article reviews
anti gapdh - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
ab275377 anti zo 1 antibody proteintech cat  (Proteintech)
97
Proteintech ab275377 anti zo 1 antibody proteintech cat
Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA <t>and</t> <t>ML-385</t> for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001
Ab275377 Anti Zo 1 Antibody Proteintech Cat, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s8790+keap1+targetmol+cat/pm41146891-52-67-70?v=Proteintech
Average 97 stars, based on 1 article reviews
ab275377 anti zo 1 antibody proteintech cat - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

Image Search Results


Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA and ML-385 for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer

doi: 10.1186/s13046-025-03625-y

Figure Lengend Snippet: Targeting of the MET receptor reduces NRF2 activity in human TNBC cell lines. A Immunoblotting analysis of pY 1234/35 MET, MET, and NRF2 in human BC cell lines. Ponceau was used as a loading control. B Immunofluorescence (left) and relative quantification analysis (right) of NRF2 (red) nuclear intensity in human TNBC cells upon 16 h of PHA treatment. DNA (Hoechst, blue). C RT-qPCR of NRF2 target genes in human TNBC cells after 16 h of PHA treatment. Actin was used as housekeeping. D Immunoblotting (top) analysis of pY 1234/35 MET, MET, and NRF2 and relative densitometric analysis (bottom) of NRF2 in human BC cell lines after 4 h of serum-free media and 10 min of HGF stimulation (50ng/mL). Vinculin was used as a loading control. E Clonogenic assays (top) and relative quantification of the number of colonies (bottom) on MDA-MB-231, BT-549 and MCF10-A cells treated with PHA and ML-385 for 72 h. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B ) Mann-Whitney test according to the normal distribution. C Multiple t -test. D Unpaired t -test. E One-way ANOVA statistical test. PHA: PHA-665752 1 or 2 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);

Techniques: Activity Assay, Western Blot, Control, Immunofluorescence, Quantitative Proteomics, Quantitative RT-PCR, MANN-WHITNEY

MET or NRF2 targeting enhances Paclitaxel sensitivity of TNBC cells. Cell viability of MGT-13 ( A ) and BT-549 ( B ) cells exposed to PTX in combination with PHA or ML-385. Percentage of cell viability in presence of drugs compared to controls (untreated cells) is indicated using a colour scale (from green to red). C-D Top panel: matrix synergy plot representing the synergy/antagonism score of each combination and its statistical significance calculated by Loewe model. Bottom panel: mapped to d-r surface showing the synergy distribution of drug combinations. The synergistic analysis was performed on MGT-13 ( C ) and BT-549 ( D ) cell lines. E-F Clonogenic assays on MGT-13 cells exposed to PTX in combination with PHA ( E ) or ML-385 ( F ) and treated as in Fig. 4A. G-H Histograms of flow cytometry experiments representing the percentage of dead cells upon ANNEXIN V/DAPI + staining of MGT-13 cells exposed for 72 h to PHA and PTX ( G ) or ML-385 and PTX ( H ) treatments alone or in combination. Results represent the mean of at least three independent experiments (± SEM). Statistical analysis: ( A-B-G-H ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. (In A-B, * indicate the significance respect to PTX treatment). C-D Loewe models were used for synergy score calculation by Combenefit software. PHA: PHA-665752: MET inhibitor; ML-385: NRF2 inhibitor. PTX: Paclitaxel. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer

doi: 10.1186/s13046-025-03625-y

Figure Lengend Snippet: MET or NRF2 targeting enhances Paclitaxel sensitivity of TNBC cells. Cell viability of MGT-13 ( A ) and BT-549 ( B ) cells exposed to PTX in combination with PHA or ML-385. Percentage of cell viability in presence of drugs compared to controls (untreated cells) is indicated using a colour scale (from green to red). C-D Top panel: matrix synergy plot representing the synergy/antagonism score of each combination and its statistical significance calculated by Loewe model. Bottom panel: mapped to d-r surface showing the synergy distribution of drug combinations. The synergistic analysis was performed on MGT-13 ( C ) and BT-549 ( D ) cell lines. E-F Clonogenic assays on MGT-13 cells exposed to PTX in combination with PHA ( E ) or ML-385 ( F ) and treated as in Fig. 4A. G-H Histograms of flow cytometry experiments representing the percentage of dead cells upon ANNEXIN V/DAPI + staining of MGT-13 cells exposed for 72 h to PHA and PTX ( G ) or ML-385 and PTX ( H ) treatments alone or in combination. Results represent the mean of at least three independent experiments (± SEM). Statistical analysis: ( A-B-G-H ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. (In A-B, * indicate the significance respect to PTX treatment). C-D Loewe models were used for synergy score calculation by Combenefit software. PHA: PHA-665752: MET inhibitor; ML-385: NRF2 inhibitor. PTX: Paclitaxel. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);

Techniques: Flow Cytometry, Staining, Software

MET-NRF2 axis inhibition increases ROS levels and DNA damage accumulation. Immunoblotting ( A ) and relative densitometric analysis ( B ) of p62 and HO-1 in MGT-13 and BT-549 cells exposed for 24 h to PTX in combination with PHA. Actin was used as a loading control. C-F Cytofluorimetric analyses (top) and relative histograms (bottom) of reactive oxygen species (ROS) upon DHE staining on MGT-13 ( C-D ) and BT-549 ( E-F ) cells exposed for 24 h to PTX in combination with PHA or ML-385. Confocal microscopy analysis ( G ) and relative quantification ( H ) of 8-oxo-DG (red) foci/cell in MGT-13 cells treated alone or in combination with PTX and PHA. DNA (Hoechst, blue). Confocal microscopy analysis ( I ) and relative quantification ( J ) of γH2AX (green) positive cells in MGT-13 cells treated alone or in combination with PTX and PHA. K Immunoblotting analysis of γH2AX in MGT-13 and BT-549 treated as in ( I ). Vinculin and GAPDH were used as loading control. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B-D-F-H-J ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. PHA: PHA-665752 1 or 3 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. PTX: Paclitaxel 3nM or 30nM. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer

doi: 10.1186/s13046-025-03625-y

Figure Lengend Snippet: MET-NRF2 axis inhibition increases ROS levels and DNA damage accumulation. Immunoblotting ( A ) and relative densitometric analysis ( B ) of p62 and HO-1 in MGT-13 and BT-549 cells exposed for 24 h to PTX in combination with PHA. Actin was used as a loading control. C-F Cytofluorimetric analyses (top) and relative histograms (bottom) of reactive oxygen species (ROS) upon DHE staining on MGT-13 ( C-D ) and BT-549 ( E-F ) cells exposed for 24 h to PTX in combination with PHA or ML-385. Confocal microscopy analysis ( G ) and relative quantification ( H ) of 8-oxo-DG (red) foci/cell in MGT-13 cells treated alone or in combination with PTX and PHA. DNA (Hoechst, blue). Confocal microscopy analysis ( I ) and relative quantification ( J ) of γH2AX (green) positive cells in MGT-13 cells treated alone or in combination with PTX and PHA. K Immunoblotting analysis of γH2AX in MGT-13 and BT-549 treated as in ( I ). Vinculin and GAPDH were used as loading control. Results represent the mean of at least three independent experiments (± SEM or ± SD). Statistical analysis: ( B-D-F-H-J ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. PHA: PHA-665752 1 or 3 µM, MET inhibitor. ML-385: 5 µM, NRF2 inhibitor. PTX: Paclitaxel 3nM or 30nM. ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001

Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);

Techniques: Inhibition, Western Blot, Control, Staining, Confocal Microscopy, Quantitative Proteomics

MET, SRC or NRF2 targeting improves Paclitaxel efficacy in TNBC patient-derived organoids. Organoid viability assays of PDO-21, PDO-43, and PDO-46 after PHA and PTX ( A ), ML-385 and PTX ( B ), DAS and PTX ( C ) combination treatments. D 4X digital magnification of bright-field images and relative quantification of organoids size of PDO-21 culture treated as described in ( A-B-C ). Scale bar: 400 μm. E Percentage of small, medium, and large PDO-21 treated as in ( A - B - C ). F Working model. Results represent the mean of at least three independent experiments (± SEM). Statistical analysis: ( A-B-C ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. E Two-way ANOVA followed by Tukey’s multiple comparison test (* respect to CTR, $ respect to inhibitors and # respect to PTX). PHA: PHA-665752, MET inhibitor. DAS: Dasatinib. ML-385: NRF2 inhibitor. PTX: Paclitaxel. ns: not significant; *, $, # p < 0.05; **, $$, ## p < 0.01; ***, $$$, ### p < 0.001; ****, $$$$, #### p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer

doi: 10.1186/s13046-025-03625-y

Figure Lengend Snippet: MET, SRC or NRF2 targeting improves Paclitaxel efficacy in TNBC patient-derived organoids. Organoid viability assays of PDO-21, PDO-43, and PDO-46 after PHA and PTX ( A ), ML-385 and PTX ( B ), DAS and PTX ( C ) combination treatments. D 4X digital magnification of bright-field images and relative quantification of organoids size of PDO-21 culture treated as described in ( A-B-C ). Scale bar: 400 μm. E Percentage of small, medium, and large PDO-21 treated as in ( A - B - C ). F Working model. Results represent the mean of at least three independent experiments (± SEM). Statistical analysis: ( A-B-C ) One-way ANOVA statistical test was performed for each combination compared to the drug alone. E Two-way ANOVA followed by Tukey’s multiple comparison test (* respect to CTR, $ respect to inhibitors and # respect to PTX). PHA: PHA-665752, MET inhibitor. DAS: Dasatinib. ML-385: NRF2 inhibitor. PTX: Paclitaxel. ns: not significant; *, $, # p < 0.05; **, $$, ## p < 0.01; ***, $$$, ### p < 0.001; ****, $$$$, #### p < 0.0001

Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);

Techniques: Derivative Assay, Quantitative Proteomics, Comparison